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Effect of Selenium on “Low T3 Syndrome” in
Hepatic Failure

Abstract: Triiodothyronine occurs especially
in 5’-monodeiodination of thyroxin in
peripheral tissues. Deiodination of thyroxin
mainly occurs in the liver. The enzyme which
catalyzes this reaction is a seleno-enzyme.
Deiodinase enzyme activity and the
triiodothyronine level decrease in selenium
deficiency.

Triiodothyronine levels in the carbon
tetrachloride group and carbon tetrachloride
+ selenium group were significantly lower
than in the control group (P<0.01, P<0.05,
respectively). In the carbon tetrachloride +
selenium group, the level of triiodothyronine
was higher than in the carbon tetrachloride
group (P<0.05).

After the occurrence of chronic hepatic
failure by carbon tetrachloride in rats, we
gave sodium selenite to these rats. Then, we
tried to evaluate the changes in thyroid
hormone levels.

Deiodination of thyroxin was impaired in
hepatic failure. Selenium couldn’t prevent the
inhibition of hepatic deiodination of thyroxin
completely.

Liver function tests, thyroxin and
triiodothyronine levels, and hepatic 5’deiodinase and glutathione peroxidase
enzyme activities were measured.

Key Words: Hepatic failure, Selenium,
Thyroid hormones.

Introduction
Selenium (Se) deficiency has important pathological
sequelae in both animals and in man and may cause poor
growth, impaired neutrophil function, and increased
susceptibility to infections (1–3). In man, lowered Se
status has been associated with cardiomyopathy and an
increased risk of developing certain cancers (4, 5).
Hepatic enzyme expession changes with Se deficiency,
but the mechanism is unclear (6). Thyroid hormones have
many effects on hepatic enzyme expression. The
relationships between thyroid hormones and Se had been
documented by many studies (7–10). All thyroxine (T4) is
obtained from thyroidal synthesis, but over 85% of
circulating T3 is derived from 5’–monodeiodination of T4
in peripheral tissues. 5’–monodeiodination of T4 mainly
occurs in the liver (11).
Changes in enzyme expression in Se deficiency may
also affect the peripheral thyroid hormone metabolism.
Deiodination of T4 to T3 is especially caused in the liver by
Type I 5’–deiodinase enzyme, which is a seleno–enzyme.

Therefore, Se deficiency may decrease the biologically
active T3 level. In non–thyroidal tissues, two types of
enzyme are responsible for 5’–monodeiodination of
thyroxine. The type I enzyme is present mainly in the liver
and kidney and it is inhibited by low concentrations of
propylthiouracil. The type II enzyme is found mainly in
the pituitary and in the brain (11).
The Se level is very high in the liver, the pituitary, the
renal cortex, and the pancreas tissues. The Se level
decreases in hepatic failure and in cardiovascular diseases
(11).
Decreased T3 level in hepatic failure has been
attributed to various causes (12). Because Se affects
deiodination of T4 to T3, it is possible that thyroid
hormone composition may change in hepatic failure due
to Se deficiency. After experimental hepatic failure
occurred in rats, we tried to investigate the effect of Se
injections on the T4 metabolism.

649

Effect of Selenium on “Low T3 Syndrome” in Hepatic Failure

Materials and Methods
Forty male Wistar rats were used in this study. The
rats were divided into 4 groups.
Group 1 (n=10): Carbon tetrachloride (CCl4) was
diluted in refined olive oil at a ratio of 3:2. Diluted CCl4,
at a dose of 0.15 ml/100 g, was administered
subcutaneously 3 times a week for 6 weeks. By
administering CCl4, cirrhosis was induced in these rats
(CCl4 group). Diagnosis of cirrhosis confirmed by biopsy.
Group 2 (n=10): By administering CCl4, cirrhosis was
induced in this group. Then sodium selenite, at a dose of
0.1 mg/kg, was administered intraperitoneally once a day
for one week (CCl4+Se group).

centrifuged at 1500 g for 15 minutes and the T3
concentration of the supernatants was measured with
radioimmunoassay after 10–fold dilution with
sucrose/Tris buffer (6).
Protein concentration in the homogenates was
measured by biuret reaction.
Measurement of Hepatic GSH–Px (Glutathione
peroxidase) activity
Liver tissues were homogenized in 3 volumes of 20
mM phosphate buffer containing 150 mM NaCl (pH 7.4)
and used for the measurement of GSH–Px activity.
GSH–Px activity was measured, with 0.25 mM–H2O2
as the substrate, in the presence of 5 mM–GSH (13).

Group 3 (n=10): Only refined olive oil, at a dose of
0.15 ml/100 g, was administered subcutaneously 3 times
a week for 6 weeks (Control group).

The data were expressed as Mean±SD. Differences
among groups were compared using the Mann–Whitney
U–test.

Group 4 (n=10): Refined olive oil, at a dose of 0.15
ml/100 g, was administered subcutaneously 3 times a
week for 6 weeks. Then sodium selenite, at a dose of 0.1
mg/kg, was administered intraperitoneally once a day for
one week (Se group).

Results

All rats were fed standard rat food and distilled water.
24 hours after the last feeding, all the animals were
decapited. Blood samples were taken and centrifuged at
3000 g for 10 minutes. Then, serum was exracted and
stored at –20°C. Liver function tests (Serum total
bilirubin–T. bilirubin, conjugated bilirubin–C. bilirubin,
aspartate
aminotransferase–AST,
alanine
aminotransferase–ALT, lactic dehydrogenase–LDH,
alkaline
phosphatase–ALP,
and
gamma–
glutamyltranspeptidase–GGT) were evaluated with a
Tecnicon RA, XT model autoanalyzer. Serum T4 and T3
levels were measured using radioimmunassay methods.
We used DPC test kits–Diagnostic Product Corporation,
Los Angeles, California and LKB 1261 Multigamma
gamma counter.
Preparation of tissue homogenates
Liver tissues were homogenized in 3 volumes of
buffer [0.25 M sucrose/0.05 M–Tris/HCl (pH
7.4)/mM–DDT] using a Teflon–pestle/glass–body
homogenizer (6).
Measurement of T3 production
Homogenates (2 ml) were placed into glass tubes and
incubated at 37°C for 5 min before the addition of 10 µg
of T4 dissolved in 20 µl of phosphate buffer (0.5 M; pH
7.4). At increasing time periods, 0.2 ml portions of the
homogenates were put in 0.4 ml of ethanol and mixed for
30 s on a vortex mixer. The ethanolic extracts were then
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Diagnosis
of
cirrhosis
was
confirmed
histopathologically. The results of the liver function tests
are shown in Table 1.
GSH–Px activity was measured as an index of
selenium deficiency. Hepatic GSH–Px activity was
significantly low in the CCl4 group (P<0.001). By
administering selenium, hepatic GSH–Px activity
increased. Hepatic GSH–Px activity was higher in the
CCl4+Selenium group (790.81±78.45 mU/mg protein)
than in the CCl4 group (612.15±71.00 mU/mg protein)
(P<0.01). By administering selenium, hepatic GSH–Px
activity was also increased in the selenium group relative
to the control group (P<0.01).
5’–deiodinase (5’DI) enzyme activity decreased 50%
in the CCl4 group and 20% in the CCl4+Selenium group.
After administering selenium, 5’DI enzyme activity was
increased significantly in the selenium group relative to
the control group (P<0.05).
Serum T4 level decreased insignificantly in the CCl4
group and increased insignificantly in the CCl4+Selenium
group. However, T4 level increased significantly in the
Selenium group (P<0.05).
T3 levels in the CCl4 group and CCl4+Se group were
significantly lower than in the control group (P<0.01,
P<0.05, respectively). In the CCl4+Se group, the level of
T3 was higher than in the CCl4 group (P<0.05). These
results are shown in Table 2.
In the control group, the correlation between GSH–Px
activity and 5’–Deiodinase was r=0.472 (P>0.05) and
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Control

CCl4

CCl4+Se

Se

Group

Group

Group

Group

(n=10)

(n=10)

(n=10)

(n=10)

AST (U/L)

70.20±12.21

807.15±98.06

A

708.57±100.90 A

ALT (U/L)

50.80±9.70

383.86±67.09

A

354.44±50.71

LDH (U/L)

504.67±81.90

2910.54±275.87

A

ALP (U/L)

250.29±40.50

600.13±96.23

A

588.13±90.30

A

GGT (U/L)

3.90±0.70

7.80±1.72

A

4.79±0.98

A

4.01±0.40

T. Bilirubin (mg/dl)

0.24±0.02

3.60±0.65

A

3.03±0.70

A

0.26±0.03

C. Bilirubin (mg/dl)

0.18±0.01

2.80±0.70

A

2.52±0.45

A

0.17±0.02

A

2900.60±265.98 A

Table 1.

Liver function tests.

Table 2.

Hepatic 5’–Deiodinase and
Glutathione
peroxidase
(GSH–Px) enzyme activities
and serum thyroxin (T4) and
triiodothyronine (T3) values.

73.21±11.05
49.01±7.00
512.32±79.00
275.41±34.09

CCl4 = Carbon tetrachloride
CCl4+Se = Carbon tetrachloride+selenium
Se = Selenium
AST = Aspartate aminotransferase
ALT = Alanine aminotransferase
LDH = Lactic dehydrogenase
ALP = Alkaline phosphatase
GGT = Gamma–glutamyltranspeptidase
T. Bilirubin = Total Bilirubin
C. Bilirubin = Conjugated Bilirubin
A = P<0.001 versus control

Control

GSH–Px
5’–DI

CCl4

CCl4+Se

Se

Group

Group

Group

Group

(n=10)

(n=10)

(n=10)

(n=10)

807.50±95.70
15.20±1.30

612.15±71.00 B
7.70±0.60

T4 (µg/dl)

5.37±0.95

4.60±0.87

T3 (ng/dl)

90.48±18.20

60.12±11.71

790.81±78.45

C

12.10±1.40

B

71.18±10.12

957.48±108.30

A

A

20.30±2.00

B

6.50±1.05

A

A,D

92.74±13.98

5.20±0.98

CCl4 = Carbon tetrachloride
CCl4+Se = Carbon tetrachloride+selenium
Se = Selenium
GSH–Px = Glutathione peroxidase (mU/mg protein)
5’–DI=5’–Deiodinase (fmol/min/mg)
T4 = Thyroxin
T3 = Triiodothyronine
A = P<0.05 versus control
B = P<0.01 versus control
C = P>0.001 versus control
D = P<0.05 versus CCl4 group

the correlation between GSH–Px activity and T3 was
r=0.403 (P>0.05).

correlation between GSH–Px activity and T3 was r=0.550
(P<0.05).

In the CCl4 group, the correlation between GSH–Px
activity and 5’–Deiodinase was r=0.670 (p<0.01) and the

In the CCl4+Se group, the correlation between
GSH–Px activity and 5’–Deiodinase was r=0.690
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(P<0.01) and the correlation between GSH–Px activity
and T3 was r=0.565 (P<0.05).
In the Se group, the correlation between GSH–Px
activity and 5’–Deiodinase was r=0.560 (P<0.05) and
the correlation between GSH–Px activity and T3 was
r=0.510 (P>0.05).
Discussion
T4 produces T3 and rT3. This transformation is in
balance under normal conditions. Several clinical states
such as starvation, protein calorie malnutrition, acute or
chronic illness, cirrhosis of the liver, chronic renal failure,
systemic diseases, and exercise are associated with low
serum T3 and increased serum rT3 levels due to changes
in the T4 metabolism (14–19).
Recently, it was concluded that hyperglucagonemia
may be one of the factors responsible for low serum T3
and high serum rT3 concentrations in hepatic cirrhosis.
Besides hyperglucagonemia, selenium deficiency occurs in
cirrhosis, too. Kabadi et al have suggested that glucagon
has a significant effect on the deiodination of T4 (12, 16,
18, 20). The Se level decreases in hepatic cirrhosis. Se is
present in the 5’–deiodinase enzyme structure and this
enzyme has a role in the monodeiodination of T4.
Therefore, 5’–deiodinase enzyme activity decreases in Se
deficiency (21, 22).
In this study, we observed that Se didn’t affect the
serum T3 level in normal rats. But, the T3 level decreased
in the group in which hepatic failure was induced with
CCl4. The CCl4+Se group had a significantly higher serum
T3 level than the CCl4 group (P<0.05), but a lower T3
level than the control group (P<0.05).

5’–deiodinase enzyme activity significantly decreased
after hepatic failure. By administering Se, 5’–deiodinase
enzyme activity increased. These findings were in parallel
with changes observed in the serum T3 level.
Se administered to cirrhotic rats increased GSH–Px
activity, 5’–DI activity, and the T3 level. Thus, we think
that a low serum T3 level in cirrhosis at least may
originate from Se deficiency.
5’–deiodinase enzyme activity decreases in chronically
Se deficient rats. Therefore, the serum T4 level increases
and the serum T3 level decreases. Menhold et al (8) have
observed that hepatic type I 5’–deiodinase enzyme
activity significantly decreased in chronically Se deficient
rats. They have reported that the T3 level decreased and
the T4 level increased in these rats. Beckett et al (23) have
demonstrated that Se deficiency for periods of 5 or 6
weeks in rats produced an inhibition of type I
5’–deiodinase enzyme activity in the liver and an
inhibition of type II 5’–deiodinase enzyme activity in the
brain. Inhibition of type I 5’–deiodinase and type II
5’–deiodinase activities decrease turnover of T4 to T3.
The Se level decreases in hepatic failure and the
thyroid hormone metabolism is impaired in Se deficiency.
Therefore, Se deficiency may be one of the factors
responsible for low T3 hormone levels in hepatic cirrhosis.
In our study, we observed that Se, a trace element, played
an important role in the thyroid hormone metabolism in
cirrhosis. However, we couldn’t increase the T3 level to its
normal value by administering Se to rats which had
hepatic failure. Therefore, we suggest that other factors
are also responsible for “Low T3 syndrome” in hepatic
failure. Nevertheless, we think that additional Se therapy
may be beneficial to the thyroid hormone metabolism in
hepatic failure.
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